Journal Article

Amphotericin B Lipid Complex (ABLC)-Associated Hypertension: Case Report and Review

David M. Rowles and Susan L. Fraser

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 29, issue 6, pages 1564-1565
Published in print December 1999 | ISSN: 1058-4838
Published online December 1999 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/313533
Amphotericin B Lipid Complex (ABLC)-Associated Hypertension: Case Report and Review

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Amphotericin B (AmB) continues to be the mainstay of therapy for serious fungal infections, despite its relatively toxic side-effect profile. Lipid preparations of the medication have been marketed in the past few years in an attempt to reduce some of these side effects, especially nephrotoxicity. Although 6 cases of severe hypertension associated with the use of AmB de-oxycholate have been reported in the literature, no cases of hypertension associated with a lipid-containing preparation of the medication have been reported. We report here the first case of severe hypertension associated with the infusion of AmB lipid complex (ABLC) in a patient with multiple intraperitoneal and urinary fungal pathogens. We also provide a brief review of the previously reported cases of hypertension associated with the deoxycholate formulation of AmB.

Journal Article.  1000 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.